Cited by 9Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

Protofibrillar and Fibrillar Amyloid-β Binding Proteins in Cerebrospinal Fluid

Open access
Rahman, M. Mahafuzur, Westermark, Gunilla T., Zetterberg, Henrik, Härd, Torleif, Sandgren, Mats·2018·Journal of Alzheimer’s Disease

Abstract

Aggregation and deposition of misfolded amyloid-β (Aβ) peptide in the brain is central to Alzheimer’s disease (AD). Oligomeric, protofibrillar, and fibrillar forms of Aβ are believed to be neurotoxic and cause neurodegeneration in AD, but the toxicity mechanisms are not well understood and may involve Aβ-interacting molecular partners. In a previous study, we identified potential Aβ 42 protofibrillar-binding proteins in serum and cerebrospinal fluid (CSF) using an engineered version of Aβ 42 (Aβ 42 CC) that forms protofibrils, but not fibrils. Here we studied binding of proteins to Aβ 42 fibrils in AD and non-AD CSF and compared these with protofibrillar Aβ 42 CC-binding partners. Aβ 42 fibrils sequestered 2.4-fold more proteins than Aβ 42 CC protofibrils. Proteins with selective binding to fibrillar aggregates with low nanomolar affinity were identified. We also found that protofibrillar and fibrillar Aβ-binding proteins represent distinct functional categories. Aβ 42 CC protofibrils triggered interactions with proteins involved in catalytic activities, like transferases and oxidoreductases, while Aβ 42 fibrils were more likely involved in binding to proteoglycans, growth factors and neuron-associated proteins, e.g., neurexin-1, -2, and -3. Interestingly, 10 brain-enriched proteins were identified among the fibril-binding proteins, while protofibril-extracted proteins had more general expression patterns. Both types of Aβ aggregates bound several extracellular proteins. Additionally, we list a set of CSF proteins that might have potential to discriminate between AD and non-AD CSF samples. The results may be of relevance both for biomarker studies and for studies of Aβ-related toxicity mechanisms.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3233/jad-180596

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • NRXN3 is the isoform most consistently implicated in AD pathogenesis.

    “given that this isoform has been most consistently implicated in AD pathogenesis35–39.”

    From PLCG2 downregulation impairs synaptic function and increases Alzheimer’s disease hallmarks in neuronal cultures (2026) · cites this paper as [36]

    The Novel proteins section identifies neurexin-3 among several neurexins that bound Aβ42 fibrils from AD samples only. The Discussion also mentions neurexin-3β processing, but neither section says NRXN3 is the isoform most consistently implicated in AD pathogenesis. Page numbers were not available in our copy. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • Neurexins have been shown to regulate APP synaptic functions and/or modulate Aβ-induced synaptotoxicity.

    “neurexins have been shown to regulate APP synaptic functions and/or modulate Aβ-induced synaptotoxicity36,37,48.”

    From PLCG2 downregulation impairs synaptic function and increases Alzheimer’s disease hallmarks in neuronal cultures (2026) · cites this paper as [36]

    The Discussion reports that neurexins bind APP, and the Novel proteins section identifies neurexins binding Aβ42 fibrils in AD cerebrospinal-fluid samples (page numbers unavailable). Neither passage shows that neurexins regulate APP synaptic functions or modulate Aβ-induced synaptotoxicity; binding alone does not establish those functional effects. (LLM, conf=0.83)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

No citation lists for this paper

No citation lists for this paper yet — checked again daily.

References 50 · Cited by 9

Research works printed but not linked: 5

  1. Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJM, Westermark P (2016) Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid-Journal of Protein Folding Disorders 23, 209-213.
  2. Querfurth HW, LaFerla FM (2010) Alzheimer's Disease. New England Journal of Medicine 362, 329-344.
  3. McLaurin J, Yang DS, Yip CM, Fraser PE (2000) Review: Modulating Factors in Amyloid-β Fibril Formation. Journal of Structural Biology 130, 259-270.
  4. Donahue JE, Berzin TM, Rafii MS, Glass DJ, Yancopoulos GD, Fallon JR, Stopa EG (1999) Agrin in Alzheimer's disease: altered solubility and abnormal distribution within microvasculature and brain parenchyma. Proceedings of the National Academy of Sciences 96, 6468-6472.
  5. Lin Q, Cao Y, Gao J (2014) Serum Calreticulin Is a Negative Biomarker in Patients with Alzheimer's Disease. International Journal of Molecular Sciences 15, 21740.

Authors
Rahman, M. M., Westermark, G. T., Zetterberg, H., Härd, T., & Sandgren, M.
Affiliations
  • Swedish University of Agricultural Sciences (SE)
  • Uppsala University (SE)
  • Sahlgrenska University Hospital (SE)
Corresponding author
Sandgren, Mats
Venue
Journal of Alzheimer’s Disease
Published
2018-10-23
Volume
66
Issue
3
Pages
1053-1064
ISSN
  • 1387-2877 (ISSN-L)
  • 1875-8908
OpenAlex
W2897518152
Cited by
9
References
50
Citations by year
2025: 2 · 2022: 2 · 2021: 3 · 2020: 1 · 2019: 1
FWCI
0.86
Type
journal article
Language
en
Open access
Locations
  • Journal of Alzheimer s Disease (publishedVersion)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
Funders
Svenska Forskningsrådet Formas
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
amyloid-beta, protofibrils
MeSH terms
Aged, Alzheimer Disease, Amyloid, Female, Humans, Male, Middle Aged, Peptide Fragments, Protein Binding, Mass Spectrometry, Amyloid beta-Peptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review